1. Home
  2. ALHC vs MIRM Comparison

ALHC vs MIRM Comparison

Compare ALHC & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alignment Healthcare Inc.

ALHC

Alignment Healthcare Inc.

HOLD

Current Price

$22.76

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$91.35

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALHC
MIRM
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.2B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
ALHC
MIRM
Price
$22.76
$91.35
Analyst Decision
Buy
Strong Buy
Analyst Count
12
11
Target Price
$21.63
$97.55
AVG Volume (30 Days)
2.8M
833.6K
Earning Date
02-26-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,637,156,000.00
$471,794,000.00
Revenue This Year
$48.62
$54.25
Revenue Next Year
$32.25
$21.09
P/E Ratio
N/A
N/A
Revenue Growth
47.39
53.66
52 Week Low
$11.63
$36.88
52 Week High
$23.19
$93.70

Technical Indicators

Market Signals
Indicator
ALHC
MIRM
Relative Strength Index (RSI) 72.80 71.95
Support Level $20.53 $85.98
Resistance Level $23.19 $93.70
Average True Range (ATR) 0.90 3.83
MACD 0.17 0.95
Stochastic Oscillator 89.68 87.40

Price Performance

Historical Comparison
ALHC
MIRM

About ALHC Alignment Healthcare Inc.

Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: